SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Furosemide for Injection in the ...

BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to ...

Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- ...

BURLINGTON, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to ...

Hikma has launched furosemide injection, in 20mg/2ml, 40mg/4ml, 100mg/10ml, 500mg/50ml and 1,000mg/100ml presentations. “Hikma is introducing the first FDA approved 50ml and 100ml presentations to the ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved an expanded indication of self-administered subcutaneous furosemide for patients with HF. The ...

WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced two business updates—approval of the FUROSCIX ® (furosemide) ...

The pre-programmed device delivers 30mg of furosemide over the first hour followed by 12.5mg per hour for the subsequent 4 hours. The Food and Drug Administration (FDA) has approved Lasix ® ONYU ...

Credit: scPharmaceuticals. Furoscix is a pH-neutral formulation of furosemide, a loop diuretic, designed for SC administration via an on-body infusor for outpatient self-administration. Furoscix ® ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...

FUROSCIX ReadyFlow Autoinjector Could Transform Care from Hours to Seconds MannKind recently announced that the FDA accepted for review its sNDA for the FUROSCIX ReadyFlow Autoinjector for the ...

FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end ...